Alkeon Capital Management
NGNE icon

Alkeon Capital Management’s Neurogene NGNE Stock Holding History

Alkeon Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,247
Closed -$1.08M – 153
2021
Q4 		$1.08M Sell
11,247
-13,753
-55% -$1.68M ﹤0.01% 152
2021
Q3 		$3.62M Hold
25,000
– – 0.01% 170
2021
Q2 		$4.62M Hold
25,000
– – 0.01% 171
2021
Q1 		$6.16M Hold
25,000
– – 0.01% 160
2020
Q4 		$7.05M Buy
25,000
+15,000
+150% +$3.67M 0.01% 151
2020
Q3 		$2.4M Hold
10,000
– – ﹤0.01% 142
2020
Q2 		$3.32M Hold
10,000
– – 0.01% 136
2020
Q1 		$2.28M Hold
10,000
– – 0.01% 128
2019
Q4 		$2.46M Buy
+10,000
New +$996K 0.01% 123

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Alkeon Capital Management's NGNE Position: Q1 2022 in Review

Alkeon Capital Management sold out of Neurogene (NGNE) in Q1 2022, closing a stake of 11,247 shares — an estimated $1.08M sold.

Alkeon Capital Management first reported a position in NGNE in Q4 2019 and held it in 9 quarters. The position peaked at $7.05M in Q4 2020. 81 funds tracked by Wall St. Rank hold NGNE as of Q1 2022.

  • Alkeon Capital Management reported no remaining Neurogene position as of Q1 2022 after selling out during the quarter.
  • Alkeon Capital Management sold 11,247 Neurogene shares in Q1 2022, an estimated $1.08M.
  • Alkeon Capital Management first reported a position in Neurogene in Q4 2019 and held it in 9 quarters.
  • Alkeon Capital Management's Neurogene position peaked at $7.05M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Neurogene as of Q1 2022.

Based on Alkeon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.